50岁以下女性子宫癌发病率趋势及按种族/民族和组织学分型的5年相对生存率
基于SEER 2000-2019年57,128例子宫癌病例,50岁以下女性子宫癌年龄调整发病率从2000-2009年的10.1/10万升至2010-2019年的12.0/10万,年增1.7%;子宫内膜样癌5年相对生存率无显著变化,肉瘤生存率从69.8%降至66.4%。
要点
- 50岁以下女性子宫癌发病率2000-2019年年增1.7%,40岁以下及非白人种族增幅更大。
- 子宫内膜样癌5年相对生存率93.4%升至93.9%无显著差异,非子宫内膜样癌73.2%不变。
- 肉瘤虽少见但为第二常见类型,5年相对生存率从69.8%降至66.4%(P<.05)。
核心结论
- 2000至2019年50岁以下女性子宫癌发病率上升而生存率相对不变,增长主要归因于子宫内膜样癌。
- 非西班牙裔黑人、西班牙裔和非西班牙裔亚裔/太平洋岛民发病率增幅最大。
- 肉瘤虽远更罕见但为50岁以下女性第二常见子宫癌类型,预后差且生存率似随时间下降。
研究设计与样本
- 基于监测、流行病学和最终结果(SEER)项目2000-2019年显微确诊的20至49岁女性子宫癌病例,共57,128例。
- 年龄调整发病率和5年相对生存率及95%置信区间用SEER*Stat计算,比较2000-2009年与2010-2019年两个时段。
- 发病率使用行为危险因素监测系统数据校正子宫切除患病率,趋势用Joinpoint回归程序计算。
主要发现
- 子宫癌发病率从2000-2009年的10.1/10万升至2010-2019年的12.0/10万,整个时期年增1.7%。
- 20-29岁年增3.0%、30-39岁年增3.3%,高于40-49岁的1.3%;西班牙裔年增2.8%、非西班牙裔黑人2.7%、非西班牙裔亚裔/太平洋岛民2.1%,高于非西班牙裔白人的0.9%。
- 2010-2019年发病率以子宫内膜样癌最高(9.6/10万),肉瘤次之(1.2/10万),非子宫内膜样亚型为0.9/10万;子宫内膜样亚型2000-2019年年增1.9%。
- 2010-2019年子宫内膜样癌和非子宫内膜样癌发病率以非西班牙裔美洲原住民/阿拉斯加原住民最高(分别为15.2/10万和1.4/10万),非西班牙裔黑人最低(分别为6.4/10万和0.8/10万);肉瘤发病率以非西班牙裔黑人最高(1.8/10万)。
- 子宫内膜样癌5年相对生存率从2000-2009年的93.4%变为2010-2019年的93.9%(P≥.05),非子宫内膜样癌从73.2%变为73.2%(P≥.05),肉瘤从69.8%降至66.4%(P<.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uterine cancers diagnosed before age 50 years are increasing in the U.S., but changes in clinical characteristics and survival over time across racial/ethnic groups have not been previously described. OBJECTIVE: To investigate age-adjusted, hysterectomy corrected incidence rates and trends, and 5-year relative survival rates of uterine cancer in women aged <50 years, overall and stratified by race/ethnicity and histology. STUDY DESIGN: We included microscopically confirmed uterine cancer cases (diagnosed 2000-2019) in women aged 20 to 49 years from the Surveillance, Epidemiology, and End Results Program. Age-adjusted incidence and 5-year relative survival rates, and 95% confidence intervals were computed using Surveillance, Epidemiology, and End Results (SEER) ∗Stat and compared across time periods (2000-2009 and 2010-2019). Incidence rates were adjusted for hysterectomy prevalence using Behavioral Risk Factor Surveillance System data, and trends were computed using the Joinpoint regression program. RESULTS: We included 57,128 uterine cancer cases. The incidence of uterine cancer increased from 10.1 per 100,000 in 2000-2009 to 12.0 per 100,000 in 2010-2019, increasing at an annual rate of 1.7%/y for the entire period. Rising trends were more pronounced among women <40 years (3.0%/y and 3.3%/y in 20-29 and 30-39 years, respectively) than in those 40 to 49 years (1.3%/y), and among underrepresented racial/ethnic groups (Hispanic 2.8%/y, non-Hispanic-Black 2.7%, non-Hispanic-Asian/Pacific Islander 2.1%) than in non-Hispanic-White (0.9%/y). Recent (2010-2019) incidence rates were highest for endometrioid (9.6 per 100,000), followed by sarcomas (1.2), and nonendometrioid subtypes (0.9). Rates increased significantly for endometrioid subtypes at 1.9%/y from 2000 to 2019. Recent endometrioid and nonendometrioid rates were highest in non-Hispanic-Native American/Alaska Native (15.2 and 1.4 per 100,000), followed by Hispanic (10.9 and 1.0), non-Hispanic-Asian/Pacific Islander (10.2 and 0.9), non-Hispanic-White (9.4 and 0.8), and lowest in non-Hispanic-Black women (6.4 and 0.8). Sarcoma rates were highest in non-Hispanic-Black women (1.8 per 100,000). The 5-year relative survival remained unchanged over time for women with endometrioid (from 93.4% in 2000-2009 to 93.9% in 2010-2019, P≥.05) and nonendometrioid subtypes (from 73.2% to 73.2%, P≥.05) but decreased for women with sarcoma from 69.8% (2000-2009) to 66.4% (2010-2019, P<.05). CONCLUSION: Uterine cancer incidence rates in women <50 years have increased from 2000 to 2019 while survival has remained relatively unchanged. Incidence trends can be primarily attributed to increasing rates of cancers with endometrioid histology, with the greatest increases observed among non-Hispanic-Black, Hispanic, and non-Hispanic-Asian/Pacific Islander. Sarcomas, while much rarer, were the second most common type of uterine cancer among women <50 years and have poor prognosis and apparent decreasing survival over time. Rising rates of uterine cancer and the distinct epidemiologic patterns among women <50 years highlight the need for effective prevention and early detection strategies for uterine cancer in this age group.
引用
- Wijayabahu AT, Shiels MS, Arend RC, et al. Uterine cancer incidence trends and 5-year relative survival by race/ethnicity and histology among women under 50 years. Am J Obstet Gynecol. 2024. PMID: 38925206. doi:10.1016/j.ajog.2024.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。